KBY Biotech Indexv0.0.34
Search
← Pipeline|MD-IIT-621

MD-IIT-621

Phase 2/3
By MD Anderson
Source: Trial-derived·Trials: 1
Modality
Peptide
MOA
TNFi
Target
USP1
Pathway
Apoptosis
CRC
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
~May 2023
→ ~Aug 2024
Phase 2
Nov 2024
Phase 2Current
NCT04269680
1,180 pts·CRC
2024-11→TBD·Active
1,180 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2/3
Active
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT04269680Phase 2/3CRCActive1180PASI75
Competitors (10)
DrugCompanyPhaseTargetMOA
ABB-2476AbbViePhase 1/2USP1FcRni
AZN-7403AstraZenecaPhase 2/3FGFRTNFi
TAK-8262TakedaNDA/BLATauTNFi
TalalemzoparlimabGilead SciencesPhase 1FcRnTNFi
RibozanubrutinibGenmabApprovedGPRC5DTNFi
369-789Hansoh PharmaPhase 3PI3KαTNFi
TezesotorasibEnlivenPhase 2USP1MALT1i
RimatinibVentyx BioPhase 1CD20TNFi
ETN-506389bioPhase 1/2USP1Anti-Tau
TalatuximabProtagonistPhase 2B7-H3TNFi